Step Down From Scheduled Inhaled Corticosteroids (ICS) Plus As-Needed Fast-Acting Beta-Agonists (FABA) to As-Needed...

Area of Science:

• Pulmonology
• Clinical Medicine
• Pharmacology

Background:

• Standard asthma management involves scheduled inhaled corticosteroids (ICS) and as-needed fast-acting beta-agonists (FABA).
• The comparative efficacy and safety of reducing ICS dosage by stepping down treatment remain under investigation.

Purpose of the Study:

• To evaluate the effectiveness and safety of stepping down from scheduled ICS plus as-needed FABA to as-needed ICS/FABA in stable asthma patients.
• To compare outcomes including exacerbations, asthma control, quality of life, lung function, and adverse events.

Main Methods:

• Systematic literature search of randomized controlled trials (RCTs) across major databases (MEDLINE, EMBASE, Cochrane Central, WHO ICTRP).
• Meta-analysis using random-effects models to synthesize data on key asthma outcomes.
• Certainty of evidence assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.

Main Results:

• Seven RCTs involving 2485 patients were included.
• No significant differences were observed in severe exacerbations, asthma quality of life, lung function, or severe adverse events between groups.
• Asthma control slightly favored scheduled ICS, but the effect was trivial; cumulative ICS dose was significantly lower in the as-needed ICS group.

Conclusions:

• Stepping down to as-needed ICS/FABA in stable asthma is noninferior for asthma control and quality of life compared to standard care.
• This strategy leads to reduced cumulative inhaled corticosteroid exposure.
• Evidence for these outcomes is rated as having moderate certainty.